

Editorial



Balancing Between Ischemic and Bleeding Risk in PCI Patients With ‘Bi-Risk’

Mahn-Won Park , MD, PhD

Division of Cardiology, Daejeon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Daejeon, Korea

OPEN ACCESS

Received: Jan 12, 2022

Accepted: Feb 3, 2022

Published online: Feb 22, 2022

Correspondence to

Mahn-Won Park, MD, PhD

Division of Cardiology, Daejeon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, 64, Daeheung-ro, Jung-gu, Daejeon 34943, Korea.

Email: pmw6193@catholic.ac.kr

Copyright © 2022. The Korean Society of Cardiology

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<https://creativecommons.org/licenses/by-nc/4.0>) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

ORCID iDs

Mahn-Won Park 

<https://orcid.org/0000-0001-5293-8461>

Funding

The author received no financial support for the research, authorship, and/or publication of this article.

Conflict of Interest

The author has no financial conflicts of interest.

Data Sharing Statement

The data generated in this study is available

► See the article “Ticagrelor Monotherapy After 3-Month Dual Antiplatelet Therapy in Acute Coronary Syndrome by High Bleeding Risk: The Subanalysis From the TICO Trial” in volume 52 on page 324.

Use of dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 inhibitor is the key for the prevention of ischemic complications in patients with acute coronary syndromes (ACSs) as well as in those undergoing percutaneous coronary intervention (PCI).¹⁾ However, DAPT also increases the risk of bleeding complications, which have shown a similar prognostic impact compared to that of thrombotic events.²⁾³⁾ Especially, in ACS patients, since current guideline recommends at least 12 months of DAPT duration with potent P2Y12 inhibitors (ticagrelor or prasugrel), the bleeding risk is much higher than in non-ACS patients adopting shorter DAPT duration with clopidogrel. Therefore, finding optimal antiplatelet strategies without increase in bleeding is the cornerstone in the management of DAPT following PCI. The evolved stent performance and drug delivery mechanism of current generation drug-eluting stent (DES) compared to early generation DES, which significantly reduced the rate of ischemic events, provided the stage for investigating various de-escalation antiplatelet strategies,⁴⁾ especially in patients at high bleeding risk (HBR).

Various de-escalation approaches of antiplatelet treatment to find an optimal strategy for balancing ischemic and bleeding risks in patients with ACS have been tested, including potent P2Y12 inhibitor monotherapy following short DAPT, dose reduction of a potent P2Y12 inhibitor, and guided or unguided switching from potent P2Y12 inhibitors to clopidogrel. Almost all these de-escalation modalities consistently showed lower bleeding and comparable ischemic event rate compared with standard DAPT with potent P2Y12 inhibitors. In general, approximately 40% of patients undergoing PCI have HBR conditions.⁵⁾ However, patients at HBR are usually excluded or under-represented in clinical trials evaluating antiplatelet therapy in PCI. Especially, management of antithrombotic treatment in patients at HBR and high ischemic risk (e.g., ACS, complex PCI etc...) simultaneously, so called ‘bi-risk’, has represented a difficult challenge.

There are some data regarding de-escalation of antiplatelet therapy in patients at bi-risk. Recently published MASTER DAPT study investigated 1 month of DAPT as compared with a longer course of DAPT with respect to clinical outcomes in HBR patients undergoing PCI.⁶⁾ The authors have reported that 1 month of DAPT was noninferior to the continuation of therapy for at least 2 additional months with regard to the incidence of net adverse clinical

from the corresponding author(s) upon reasonable request.

The contents of the report are the author's own views and do not necessarily reflect the views of the *Korean Circulation Journal*.

events (NACEs) and major adverse cardiac or cerebral events (MACCEs) and was associated with a lower incidence of major or clinically relevant nonmajor bleeding. Interestingly, in the prespecified subgroup analysis including population with prior MI, there was no differences in terms of NACE (hazard ratio [HR], 0.83; 95% confidence interval [CI], 0.61–1.12; $p=0.22$) or MACCEs (HR, 0.86; 95% CI, 0.62–1.19; $p=0.36$) between 1 month and longer DAPT strategy, while significantly lower bleeding events in 1 months DAPT strategy (HR, 0.65; 95% CI, 0.46–0.91, $p=0.01$).⁷ Escaned et al.,⁸) also reported the results of the prespecified HBR subgroup analysis of TWILIGHT trial that is TWILIGHT-HBR study. Among ARC-HBR patients undergoing PCI who completed 3-month DAPT without experiencing major adverse events, ticagrelor monotherapy following 3-month DAPT significantly reduced primary endpoint of BARC 2,3, or 5 bleeding (6.3% vs. 11.4%; HR, 0.53; 95% CI, 0.35–0.82; $p=0.004$) without increasing ischemic events, compared with continuing ticagrelor plus aspirin. In addition, ARC-HBR patients experienced higher bleeding (8.9% vs. 4.7%; HR, 1.95; 95% CI, 1.54–2.48; $p<0.001$) and ischemic events (6.1% vs. 3.6%; HR, 1.70; 95% CI, 1.27–2.26; $p<0.001$) rates than non-HBR patients.

In this issue of the *Korean Circulation Journal* published the post-hoc analysis of TICO (The Ticagrelor Monotherapy After 3 Months in the Patients Treated With New Generation Sirolimus-eluting Stent for Acute Coronary Syndrome) trial in patients at HBR.⁹ The main result of TICO trial was that among patients with ACS treated with DES, ticagrelor monotherapy after 3 months of DAPT, compared with ticagrelor-based 12-month DAPT, resulted in a modest but statistically significant reduction in terms of 3 to 12-month NACE (HR, 0.66; 95% CI, 0.48–0.92; $p=0.01$), mainly by reducing the bleeding events without increase of ischemic events.¹⁰ In this HBR subgroup analysis of TICO trial, the overall population ($n=2,980$) was classified into HBR and non-HBR groups according to the ARC-HBR criteria (HBR patients, $n=453$ [15.2%]) and PRECISE-DAPT score (≥ 25) (HBR patients, $n=504$ [16.9%]). Consistent with the main study results, ticagrelor monotherapy following 3-month DAPT was associated with lower rate of NACE and major bleeding than ticagrelor based 12-month DAPT in both HBR and non-HBR groups. And, similar to the result of TWILIGHT-HBR, HBR patients showed higher rate of NACE, major bleeding and ischemic events than non-HBR patients regardless of two HBR definitions. These findings may provide some clinical evidence of short DAPT followed by potent P2Y12 inhibitor monotherapy in ACS patients at HBR, that is the patients who have 'bi-risk.' However, this post-hoc analysis have some limitations. There is an issue of underpower. In the current study, the proportion of HBR patients was only 15–16% of overall population. Moreover, the proportion of HBR patients maintaining ticagrelor monotherapy was just 7%. Thus, due to the small sample size of HBR patients and low incidence of primary endpoint events, it is hard to draw confirmative conclusions on clinical benefit of ticagrelor monotherapy following short DAPT in the ACS patients with HBR. This may be partly by the exclusion criteria of TICO trial, which excluded patients with increased risk of bleeding. In general, HBR patients comprise about 40% of PCI population in a real-world setting. Therefore, caution is needed in applying this result into our daily clinical practice and well-designed dedicated trials enrolling patients with both ischemic and bleeding risk simultaneously are essential.

REMAINING ISSUES

Regarding potent P2Y12 inhibitor monotherapy following short DAPT in ACS population, while there has been an abundant data using ticagrelor, there is a paucity of data using

prasugrel. However, theoretically, since prasugrel have similar antiplatelet potency to ticagrelor, we may postulate that prasugrel also would be clinically efficacious. Next issues are how long we should continue potent P2Y12 inhibitor monotherapy and how to change potent P2Y12 inhibitors to other agents in ACS population. We have several options switching to low dose of ticagrelor or prasugrel, or clopidogrel or aspirin. In order to decide optimal antithrombotic strategy in 'bi-risk' patients, we need a very careful tailored approach considering patient's comorbidities, lesion and procedure complexity all together.

REFERENCES

1. Kim HK, Ahn Y, Chang K, et al. 2020 Korean Society of Myocardial Infarction expert consensus document on pharmacotherapy for acute myocardial infarction. *Korean Circ J* 2020;50:845-66.
[PUBMED](#) | [CROSSREF](#)
2. Mehran R, Pocock SJ, Stone GW, et al. Associations of major bleeding and myocardial infarction with the incidence and timing of mortality in patients presenting with non-ST-elevation acute coronary syndromes: a risk model from the ACUITY trial. *Eur Heart J* 2009;30:1457-66.
[PUBMED](#) | [CROSSREF](#)
3. Valgimigli M, Costa F, Lokhnygina Y, et al. Trade-off of myocardial infarction vs. bleeding types on mortality after acute coronary syndrome: lessons from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) randomized trial. *Eur Heart J* 2017;38:804-10.
[PUBMED](#)
4. Piccolo R, Bona KH, Efthimiou O, et al. Drug-eluting or bare-metal stents for percutaneous coronary intervention: a systematic review and individual patient data meta-analysis of randomised clinical trials. *Lancet* 2019;393:2503-10.
[PUBMED](#) | [CROSSREF](#)
5. Cao D, Mehran R, Dangas G, et al. Validation of the academic research consortium high bleeding risk definition in contemporary PCI patients. *J Am Coll Cardiol* 2020;75:2711-22.
[PUBMED](#) | [CROSSREF](#)
6. Valgimigli M, Frigoli E, Heg D, et al. Dual antiplatelet therapy after PCI in patients at high bleeding risk. *N Engl J Med* 2021;385:1643-55.
[PUBMED](#) | [CROSSREF](#)
7. TCT. MASTER-DAPT: A Randomized Trial of Abbreviated Antiplatelet Therapy - Outcomes in High Bleeding Risk Patients With High Thrombotic and Ischemic Risk 2021 [Internet]. New York (NY): TCT; 2021 [cited year month day]. Available from: <https://www.tctmd.com/slide/master-dapt-randomized-trial-abbreviated-antiplatelet-therapy-outcomes-high-bleeding-risk>.
8. Escaned J, Cao D, Baber U, et al. Ticagrelor monotherapy in patients at high bleeding risk undergoing percutaneous coronary intervention: TWILIGHT-HBR. *Eur Heart J* 2021;42:4624-34.
[PUBMED](#) | [CROSSREF](#)
9. Lee YJ, Suh Y, Kim JS, et al. Ticagrelor monotherapy after 3-month dual antiplatelet therapy in acute coronary syndrome by high bleeding risk: the subanalysis from the TICO trial. *Korean Circ J* 2022;52:324-37.
[PUBMED](#) | [CROSSREF](#)
10. Kim BK, Hong SJ, Cho YH, et al. Effect of ticagrelor monotherapy vs ticagrelor with aspirin on major bleeding and cardiovascular events in patients with acute coronary syndrome: the TICO randomized clinical trial. *JAMA* 2020;323:2407-16.
[PUBMED](#) | [CROSSREF](#)